These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

98 related articles for article (PubMed ID: 8998191)

  • 21. Prostate specific antigen through the years.
    Kouriefs C; Sahoyl M; Grange P; Muir G
    Arch Ital Urol Androl; 2009 Dec; 81(4):195-8. PubMed ID: 20608139
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Predictive value of the international prostate symptom score for positive prostate needle biopsy in the low-intermediate prostate-specific antigen range.
    Kefi A; Irer B; Ozdemir I; Tuna B; Goktay Y; Yorukoğlu K; Esen A
    Urol Int; 2005; 75(3):222-6. PubMed ID: 16215309
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Scientists hopeful as they uncover molecular clues to prostate cancer.
    Vanchieri C
    J Natl Cancer Inst; 2005 Feb; 97(3):168-9. PubMed ID: 15687357
    [No Abstract]   [Full Text] [Related]  

  • 24. Prostatic specific antigen (PSA).
    Alberti C
    Minerva Urol Nefrol; 1993 Jun; 45(2):83-4. PubMed ID: 7694380
    [No Abstract]   [Full Text] [Related]  

  • 25. The Prostate Health Index: Its Utility in Prostate Cancer Detection.
    Lepor A; Catalona WJ; Loeb S
    Urol Clin North Am; 2016 Feb; 43(1):1-6. PubMed ID: 26614024
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Detection of prostate-specific antigen- or prostate-specific membrane antigen-positive circulating cells in prostatic cancer patients: clinical implications.
    Millon R; Jacqmin D; Muller D; Guillot J; Eber M; Abecassis J
    Eur Urol; 1999 Oct; 36(4):278-85. PubMed ID: 10473985
    [TBL] [Abstract][Full Text] [Related]  

  • 27. [Emerging biomarkers for the diagnosis, staging and prognosis of prostate cancer].
    Mazzola CR; Ghoneim T; Shariat SF
    Prog Urol; 2011 Jan; 21(1):1-10. PubMed ID: 21193139
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Repeating the measurement of prostate-specific antigen in symptomatic men can avoid unnecessary prostatic biopsy.
    Mishra VC; Motiwala HG
    BJU Int; 2004 May; 93(7):1116-7. PubMed ID: 15142181
    [No Abstract]   [Full Text] [Related]  

  • 29. The age old question: who benefits from prostate cancer treatment?
    Loeb S
    BJU Int; 2014 Jan; 113(1):4. PubMed ID: 24330057
    [No Abstract]   [Full Text] [Related]  

  • 30. Independent prognostic value of the 67-kd laminin receptor in human prostate cancer.
    Waltregny D; de Leval L; Ménard S; de Leval J; Castronovo V
    J Natl Cancer Inst; 1997 Aug; 89(16):1224-7. PubMed ID: 9274918
    [No Abstract]   [Full Text] [Related]  

  • 31. [New serum markers in prostate carcinoma and their application to artificial neural networks].
    Stephan C; Jung K; Cammann H; Kramer J; Kristiansen G; Loening SA; Lein M
    Urologe A; 2007 Sep; 46(9):1084-6. PubMed ID: 17641867
    [No Abstract]   [Full Text] [Related]  

  • 32. Technical tip: transperineal ultrasound-guided needle biopsy of the prostate in the postproctectomy patient.
    Lee JY
    J Endourol; 1993 Feb; 7(1):75-7. PubMed ID: 7683234
    [No Abstract]   [Full Text] [Related]  

  • 33. [Clinical utility of available diagnostic tests in prostatic carcinoma. Results of 500 biopsies. I. PSA, PSA density, and predicted PSA].
    Rodríguez Rodríguez R; Mayayo Dehesa T; Galbis Sanjuan F; Jiménez Cidre M; Burgos Revilla FJ; Allona Almagro A; Gomez dos Santos V
    Arch Esp Urol; 1997 May; 50(4):333-8. PubMed ID: 9313041
    [TBL] [Abstract][Full Text] [Related]  

  • 34. The quest for the perfect prostate biopsy continues.
    Gomella LG
    J Urol; 2012 Jun; 187(6):1954-5. PubMed ID: 22503025
    [No Abstract]   [Full Text] [Related]  

  • 35. [Prostate cancer screening: no proof of the benefit].
    Laplanche A; Hill C
    Presse Med; 2009 Oct; 38(10):1393-5. PubMed ID: 19647979
    [No Abstract]   [Full Text] [Related]  

  • 36. [German Cancer Society e.V. S3 guideline for PSA determination in diagnosis of prostatic carcinoma].
    Rübben H; Schalkhäuser K; Wolff J; Luboldt HJ;
    Onkologie; 2003 Feb; 26(1):88-9. PubMed ID: 12661558
    [No Abstract]   [Full Text] [Related]  

  • 37. [PSA and blood test diagnostics of prostate cancer].
    Seikkula H; Pettersson K; Boström PJ
    Duodecim; 2015; 131(17):1547-52. PubMed ID: 26548101
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Development of nomogram to non-steroidal antiandrogen sequential alternation in prostate cancer for predictive model.
    Kamiya N; Suzuki H; Nishimura K; Fujii M; Okegawa T; Matsuda T; Morita T; Takihana Y; Ozono S; Namiki M; Matsubara A; Ichikawa T; Miki T
    Jpn J Clin Oncol; 2014 Mar; 44(3):263-9. PubMed ID: 24516203
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Potential establishment of lung metastatic xenograft model of androgen receptor-positive and androgen-independent prostate cancer (C4-2B).
    Yamamichi F; Matsuoka T; Shigemura K; Kawabata M; Shirakawa T; Fujisawa M
    Urology; 2012 Oct; 80(4):951.e1-7. PubMed ID: 22920407
    [TBL] [Abstract][Full Text] [Related]  

  • 40. What are the factors associated with short prostate specific antigen doubling time after radical prostatectomy? A report from the SEARCH database group.
    Teeter AE; Bañez LL; Presti JC; Aronson WJ; Terris MK; Kane CJ; Amling CL; Freedland SJ;
    J Urol; 2008 Nov; 180(5):1980-4; discussion 1985. PubMed ID: 18801519
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.